Industry Newsroom

Lilly Asia Leads USD90m Series B for Chinese Biotech Regor Therapeutics

Lilly Asia Ventures led a USD90m Series B for Regor Therapeutics, a China-based clinical stage biotechnology company dedicated to the discovery of innovative medicines to treat cancer, immune disorders, and metabolic diseases. Loyal Valley Capital, Lanting Capital, TF Capital, and Vertex Ventures China also participated in the round. Read more